natgillin/translations-raw huggingface dataset:
a first pump (2) configured to compress LNG from the LNG tank (1), and to supply the compressed LNG towards a second pump (4); 
prvu crpku (2) konfiguriranu da stlačuje LNG iz spremnika LNG (1), te da dobavlja komprimirani LNG prema drugoj crpki (4);
the second pump (4) configured to further compress the LNG at a high pressure and supply the further compressed LNG towards the high-pressure gas injection engine; 
drugu crpku (4) konfiguriranu da dodatno stlačuje LNG na visoki pritisak i da dobavlja dodatno komprimirani LNG prema visokotlačnom plinskom injekcijskom motoru;
a device configured to gasify the LNG installed downstream of the second pump, to gasify the further compressed LNG; and a fuel gas supply line (L1) connected from the LNG tank to the high-pressure gas injection engine of the vessel, a boil-off gas reliquefaction apparatus operable to reliquefy boil-off gas generated in the LNG tank including a heat exchanger (3) installed along the fuel gas supply line between the LNG tank and the high-pressure gas injection engine, and wherein the boil-off gas from an upper portion of the LNG tank (1) is in thermal communication with the compressed LNG while passing through the heat exchanger and then is supplied to the fuel gas supply line. 
uređaj konfiguriran da uplinjava LNG koji je postavljen nizvodno od druge crpke, za uplinjavanje dodatno komprimiranog LNG; te vod za dobavu pogonskog plina (L1) spojen od spremnika LNG na visokotlačni plinski injekcijski motor plovila, uređaj za ukapljivanje isparenog plina koji radi tako da ukapljuje ispareni plin koji nastaje u spremniku LNG uključujući izmjenjivač topline (3) postavljen uzduž voda za dobavu pogonskog plina između spremnika LNG i visokotlačnog plinskog injekcijskog motor, te naznačen time da je ispareni plin iz gornjeg dijela spremnika LNG (1) u toplinskoj komunikaciji s komprimiranim LNG dok prolazi kroz izmjenjivač topline i zatim se dovodi u vod za dobavu pogonskog plina.
A method of supplying fuel gas to a high-pressure gas injection engine of a vessel except an LNG carrier in which an LNG tank (1) is provided, comprising: compressing LNG by a first pump (2), and supplying the compressed LNG towards a second pump (4) to further compress the LNG to meet the pressure requirements of the high-pressure gas injection engine, and then gasifying the LNG; 
Postupak dobave pogonskog plina u visokotlačni plinski injekcijski motor plovila osim za LNG tanker u kojem je predviđen spremnik LNG (1), koji sadrži: komprimiranje LNG pomoću prve crpke (2), i dobavu stlačenog LNG prema drugoj crpki (4) koja dodatno komprimira LNG kako bi se udovoljilo zahtjevima tlaka za visokotlačni plinski injekcijski motor, te zatim uplinjavanje LNG;
reliquefying boil-off gas generated in the LNG tank (1); and exchanging heat between the LNG to be supplied to the high-pressure gas injection engine and the boil-off gas generated in the LNG tank (1), wherein after the boil-off gas exchanges heat with the LNG, the LNG is supplied to the high-pressure gas injection engine, and the boil-off gas is reliquefied and then returned to the high-pressure gas injection engine. 
ukapljivanje isparenog plina stvorenog u spremniku LNG (1); te izmjenjivanje topline između LNG koji se treba dovesti u visokotlačni plinski injekcijski motor i isparenog plina stvorenog u spremniku LNG (1), naznačen time da nakon što ispareni plin izmjeni toplinu s LNG, navedeni LNG se dobavlja u visokotlačni plinski injekcijski motor, te se ispareni plin ukapljuje i potom vraća u visokotlačni plinski injekcijski motor.
The method according to claim 6 wherein the boil-off gas exchanges heat with the LNG, improving reliquefaction efficiency. 
Postupak prema zahtjevu 6 naznačen time da ispareni plin izmjenjuje toplinu s LNG, radi poboljšanja učinkovitosti ukapljivanja.
The host cell according to claim 7 wherein the peptide is secreted or expressed on the membrane surface of the cell. 
Stanica domaćin u skladu s patentnim zahtjevom 7, naznačena time što se peptid izlučuje ili eksprimira na membranskoj površini stanice.
The peptide of claim 10 or 11 in which the disease is selected from the group consisting of arthritic disease, tumor metastasis, diabetic retinopathy, psoriasis, chronic inflammation, arteriosclerosis or tumor. 
Peptid u skladu s patentnim zahtjevom 10 ili 11, naznačen time što se bolest bira iz skupine koju čine artritična bolest, tumorska metastaza, dijabetična retinopatija, psorijaza, kronična upala, arterioskleroza ili tumor.
The peptide of claim 12 in which the tumor is selected from the group of: sarcoma, carcinoma, carcinoid, bone tumor or neuroendocrine tumor. 
Peptid u skladu s patentnim zahtjevom 12, naznačen time što se tumor bira iz skupine koju čine: sarkom, karcinom, karcinoid, tumor kostiju ili neuroendokrini tumor.
A peptide of claims 1 to 4 for use against as disease associated with uncontrolled FGF2-dependent proliferation of fibroblasts or smooth muscular cells, cicatrization linked to excessive fibroblastic response, and restenosis after angioplastic. 
Peptid u skladu s patentnim zahtjevima 1 do 4, naznačen time što je namijenjen upotrebi protiv bolesti povezane s nekontroliranom proliferaciji fibroblasta ili stanica glatkih mišića ovisnoj o FGF2, cikatrizacijom povezanom s prekomjernim odgovorom fibroblasta, te restenozom nakon angioplastike.
A pharmaceutical composition comprising a therapeutically effective amount of the peptide according to any of claims 1-4 and suitable diluents and/or excipients and/or adjuvants. 
Farmaceutski pripravak, naznačen time što sadrži terapijski djelotvorna količinu peptida u skladu s bilo kojim od patentnih zahtjeva 1-4, kao i pogodne razrjeđivače i/ili pomoćne tvari i/ili adjuvanse.
A compound according to any one of Claims 1 to 5, or a salt or solvate thereof for use in the prophylaxis or treatment of cancer, cancer metastasis, depression or cognitive function disorder. 
Farmaceutska tvar namijenjena profilaksi ili liječenju raka, metastaza raka, depresije ili poremećaja kognitivnih funkcija, naznačena time što kao aktivni sastojak sadrži spoj u skladu s patentnim zahtjevom 1, ili njegovu sol ili solvat.
a light chain CDR1 sequence comprising the amino acid sequence of SEQ ID NO:13; 
CDR1 slijed lakog lanca koji sadrži aminokiselinski slijed SEQ ID NO:13;
a light chain variable domain sequence selected from the group consisting of: 
varijabilnu domenu lakog lanca izabranu iz grupe koja sadrži:
a sequence of amino acids at least 80% identical to SEQ ID NO:363; 
aminokiseline koje imaju slijed najmanje 80% identičan slijedu SEQ ID NO:363;
a sequence of amino acids encoded by a polynucleotide sequence that is at least 80% identical to SEQ ID NO:360; 
slijed aminokiselina kodiran polinukleotidnim slijedom koji je najmanje 80% identičan slijedu SEQ ID NO:360;
a sequence of amino acids that is at least 80% identical to SEQ ID NO:361; 
slijed aminokiselina najmanje 80% identičan slijedu SEQ ID NO:361;
applying said core layer (1) between a lower (5) and an upper mould surface (9); 
Nanošenje jezgrenog sloja (1) između donje (5) i gornje (9) površine prešanja;
A process according to claim 1 or 2, characterised in that said foamable composition (7) is formulated to produce a foam having a free rise density of between 20 and 100 kg/m3. 
Postupak prema zahtjevu 1 ili 2, naznačen time da je pjenasti sastav (7) tako formuliran, da postiže pjenastu tvar slobodnog porasta gustoće između 20 i 100 kg/m3.
A process according to any one of the claims 1 to 6, characterised in that the open-cell foam consists of a material which substantially does not absorb the foamable composition. 
Postupak prema jednom od zahtjeva 1 do 7, naznačen time da se staničnootvorena pjenasta tvar sastoji od materijala, koji ne apsorbira pjenasti sastav.
A method of cell expansion, comprising culturing adherent cells from placental tissue under three-dimensional culturing conditions, which support cell expansion. 
Postupak ekspanzije stanice, naznačen time da sadrži kultiviranje adherentnih stromalnih stanica iz tkiva posteljice kod uvjeta trodimenzionalnog kultiviranja.
secrete of a higher level of at least one factor selected from the group consisting of SCF, IL-6, and Flt-3 than that secreted by adherent cells of placental tissue grown in a 2D culture; and/or 
luče višu razinu najmanje jednog faktora odabranog iz skupine koju čine SCF, IL-6, i Flt-3 od razine koja je izlučena s adherentnim stanicama iz tkiva posteljice uzgojenog u 2D kulturi; i/ili
assigning a likelihood of one or more future changes in renal status to the subject based on the assay result(s), wherein said one or more future changes in renal status optionally comprise one or more of a future injury to renal function, future reduced renal function, future improvement in renal function, and future acute renal failure (ARF), or wherein said one or more future changes in renal status optionally comprise a clinical outcome related to a renal injury suffered by the subject or wherein the likelihood of one or more future changes in renal status optionally is that an event of interest is more or less likely to occur within 30 days of the time at which the body fluid sample is obtained from the subject, wherein the likelihood of one or more future changes in renal status optionally is that an event of interest is more or less likely to occur within a period selected from the group consisting of 21 days, 14 days, 7 days, 5 days, 96 hours, 72 hours, 48 hours, 36 hours, 24 hours, and 12 hours, 
Postupak u skladu s patentnim zahtjevom 1 ili 2, naznačen time što navedene jedna ili više budućih promjena bubrežnog statusa uključuju jedno ili više od budućeg oštećenja funkcije bubrega, buduće smanjene funkcije bubrega, buduće poboljšanje funkcije bubrega, buduću akutnu bubrežnu insuficijenciju (ARF), te akutnu ozljedu bubrega (AKI). Postupak u skladu s patentnim zahtjevom 1, naznačen time što je vjerojatnost pojave jedne ili više budućih promjena bubrežnog statusa jest da događaj od interesa bude više ili manje vjerojatan u periodu koji se bira iz skupine koju čine 30 dana, 21 dan, 14 dana, 7 dana, 5 dana, 96 sati, 72 sata, 48 sati, 36 sati, 24 sata, te 12 sati od vremena kada je uzet uzorak tjelesne tekućine iz subjekta.
a measured concentration of Coagulation factor VII, a measured concentration of CA19-9. 
izmjerene koncentracija čimbenika zgrušavanja VII, izmjerene koncentracije CA19-9.
optionally in RIFLE stage 0 or R, and said correlating step comprises assigning a likelihood that the subject will reach RIFLE stage I or F within 72 hours, within 48 hours or within 24 hours, wherein the subject is optionally in RIFLE stage 0 or R, and said correlating step comprises assigning a likelihood that the subject will reach RIFLE stage F within 72 hours, within 48 hours or within 24 hours or 
može biti u RIFLE stadiju 0 ili R, a navedeni korak koreliranja obuhvaća pridruživanje vjerojatnosti da subjekt dospije u RIFLE stadij I ili F unutar 72 sata, unutar 48 sati ili unutar 24 sata, gdje subjekt može biti u RIFLE stadiju 0 ili R, a navedeni korak koreliranja obuhvaća pridruživanje vjerojatnosti da subjekt dospije u RIFLE stadij F unutar 72 sata, unutar 48 sati ili unutar 24 sata ili
optionally in RIFLE stage R, and said correlating step comprises assigning a likelihood that the subject will reach RIFLE stage I or F within 72 hours, within 48 hours or within 24 hours, or wherein the subject is optionally in RIFLE stage R, and said correlating step comprises assigning a likelihood that the subject will reach RIFLE stage F within 72 hours, within 48 hours or within 24 hours. 
može biti u RIFLE stadiju R, a navedeni korak koreliranja obuhvaća pridruživanje vjerojatnosti da subjekt dospije u RIFLE stadij I ili F unutar 72 sata, unutar 48 sati ili unutar 24 sata, ili gdje subjekt može biti u RIFLE stadiju R, a navedeni korak koreliranja obuhvaća pridruživanje vjerojatnosti da subjekt dospije u RIFLE stadij F unutar 72 sata, unutar 48 sati ili unutar 24 sata.
A method according to one of claims 1-4, wherein the subject is in RIFLE stage 0, R, or I, and said correlating step comprises assigning a likelihood that the subject will reach RIFLE stage F within 72 hours, within 48 hours or within 24 hours, wherein the subject is optionally in RIFLE stage I, and said correlating step comprises assigning a likelihood that the subject will reach RIFLE stage F within 72 hours, within 48 hours or within 24 hours. A method according to one of claims 1-4, wherein 
Postupak u skladu s bilo kojim od patentnih zahtjeva 1-6, naznačen time što je subjekt u RIFLE stadiju 0, R ili I, a navedeni korak koreliranja obuhvaća pridruživanje vjerojatnosti da subjekt dospije u RIFLE stadij F unutar 72 sata, unutar 48 sati ili unutar 24 sata, gdje subjekt može biti u RIFLE stadiju I, a navedeni korak koreliranja obuhvaća pridruživanje vjerojatnosti da subjekt dospije u RIFLE stadij F unutar 72 sata, unutar 48 sati ili unutar 24 sata.
the subject is not in acute renal failure, 
kod subjekta nije došlo do akutne bubrežne insuficijencije,
the subject has not experienced a 3-fold or greater increase in serum creatinine over a baseline value determined prior to the time at which the body fluid sample is obtained, 
kod subjekta nije došlo do 3 puta većeg ili još većeg porasta kreatinina u serumu u odnosu na polaznu vrijednost određenu prije vremena kada je uzet uzorak tjelesne tekućine,
the subject has a urine output of at least 0.5 ml/kg/hr over the 12 hours preceding the time at which the body fluid sample is obtained, 
subjekt izdaje mokraću u količini od najmanje 0,5 ml/kg na sat tijekom 12 sati prije vremena kada je uzet uzorak tjelesne tekućine,
the subject (i) has not experienced a 1.5-fold or greater increase in serum creatinine over a baseline value determined prior to the time at which the body fluid sample is obtained, (ii) has a urine output of at least 0.5 ml/kg/hr over the 12 hours preceding the time at which the body fluid sample is obtained, and (iii) has not experienced an increase of 0.3 mg/dL or greater in serum creatinine over a baseline value determined prior to the time at which the body fluid sample is obtained, 
kod subjekta (i) nije došlo do 1,5 puta većeg ili još većeg porasta kreatinina u serumu u odnosu na polaznu vrijednost određenu prije vremena kada je uzet uzorak tjelesne tekućine, (ii) izdaje mokraću u količini od najmanje 0,5 ml/kg na sat tijekom 12 sati prije vremena kada je uzet uzorak tjelesne tekućine, a kod (iii) nije došlo do porasta od 0,3 mg/dl ili većeg kreatinina u serumu u odnosu na polaznu vrijednost određenu prije vremena kada je uzet uzorak tjelesne tekućine,
the subject (i) has not experienced a 2-fold or greater increase in serum creatinine over a baseline value determined prior to the time at which the body fluid sample is obtained, (ii) has a urine output of at least 0.5 ml/kg/hr over the 2 hours preceding the time at which the body fluid sample is obtained, and (iii) has not experienced an increase of 0.3 mg/dL or greater in serum creatinine over a baseline value determined prior to the time at which the body fluid sample is obtained, 
kod subjekta (i) nije došlo do 2 puta većeg ili još većeg porasta kreatinina u serumu u odnosu na polaznu vrijednost određenu prije vremena kada je uzet uzorak tjelesne tekućine, (ii) izdaje mokraću u količini od najmanje 0,5 ml/kg na sat tijekom 2 sata prije vremena kada je uzet uzorak tjelesne tekućine, a kod (iii) nije došlo do porasta od 0,3 mg/dl ili većeg kreatinina u serumu u odnosu na polaznu vrijednost određenu prije vremena kada je uzet uzorak tjelesne tekućine,
the subject has a urine output of at least 0.3 ml/kg/hr over the 24 hours preceding the time at which the body fluid sample is obtained, or anuria over the 12 hours preceding the time at which the body fluid sample is obtained or 
subjekt izdaje mokraću u količini od najmanje 0,3 ml/kg na sat tijekom 24 sata prije vremena kada je uzet uzorak tjelesne tekućine, ili ima anuriju tijekom 12 sati prije vremena kada je uzet uzorak tjelesne tekućine ili
the subject (i) has not experienced a 3-fold or greater increase in serum creatinine over a baseline value determined prior to the time at which the body fluid sample is obtained, (ii) has a urine output of at least 0.3 ml/kg/hr over the 24 hours preceding the time at which the body fluid sample is obtained, or anuria over the 12 hours preceding the time at which the body fluid sample is obtained, and (iii) has not experienced an increase of 0.3 mg/dL or greater in serum creatinine over a baseline value determined prior to the time at which the body fluid sample is obtained. 
kod subjekta (i) nije došlo do 3 puta većeg ili još većeg porasta kreatinina u serumu u odnosu na polaznu vrijednost određenu prije vremena kada je uzet uzorak tjelesne tekućine, (ii) izdaje mokraću u količini od najmanje 0,3 ml/kg na sat tijekom 24 sata prije vremena kada je uzet uzorak tjelesne tekućine, ili ima anuriju tijekom 12 sati prije vremena kada je uzet uzorak tjelesne tekućine, a kod (iii) nije došlo do porasta od 0,3 mg/dl ili većeg kreatinina u serumu u odnosu na polaznu vrijednost određenu prije vremena kada je uzet uzorak tjelesne tekućine.
said reagents comprise one or more binding reagents, each of which specifically binds a kidney injury marker, wherein a plurality of binding reagents are optionally contained in a single assay device or 
navedeni reagensi uključuju jedan ili više vežućih reagensa, od kojih se svaki specifično veže na marker ozljede bubrega, gdje jedan uređaj za ispitivanje može sadržavati više vežućih reagensa ili
at least one of said assays is configured as a sandwich binding assay or at least one of said assays is configured as a competitive binding assay, and wherein said one or more assays optionally comprise assays that detect Insulin-like growth factor-binding protein 7. 
najmanje jedno od navedenih ispitivanja je podešeno kao ispitivanje na vezanje u sendviču ili najmanje jedno od navedenih ispitivanja je podešeno kao ispitivanje na kompetitivno vezanje, i gdje navedeno jedno ili više ispitivanja može uključivati ispitivanja kojima se detektira protein 7 koji veže inzulinu sličan čimbenik rasta.
An isolated antibody or functional part thereof which is capable of specifically binding respiratory syncytial virus (RSV) F antigen, and wherein the antibody or functional part thereof comprises: 
Izolirano protutijelo ili njegov funkcionalni dio koji je sposoban specifično vezati F antigen respiratornog sincicijskog virusa (RSV), te je naznačeno time da protutijelo ili njegov funkcionalni dio sadrži:
The isolated nucleic acid sequence of claim 4, wherein the nucleic acid sequence comprises heavy and light chain nucleotide sequences selected from the group consisting of: 
Izolirana sekvenca nukleinske kiseline prema zahtjevu 4, naznačena time da sekvenca nukleinske kiseline sadrži nukleotidne sekvence teškog i lakog lanca koje su izabrane iz skupine koju čine:
A cell expressing the nucleic acid sequence of claim 4 or 5. 
Stanica naznačena time da izražava sekvencu nukleinske kiseline prema zahtjevu 4 ili 5.
providing at least a core layer (1) for said article, which core layer (1) comprises a flexible, open-cell foam; 
Priprema najmanje jednog sloja jezgre (1) za proizvod, pri čemu sloj jezgre (1) obuhvaća fleksibilnu otvorenostaničnu pjenu s otvorenim porama,
allowing the sprayed, curable, foamable composition (7) to penetrate at least partially by gravity into the open-cell foam of the core layer (1); 
Dopuštanje, da sprejani, očvrščujući, pjenušavi sastav (7) najmanje djelomice prodire putem sileteže u staničnootvorenu pjenastu tvar jezgrenog sloja (1);
A process according to claim 1, characterised in that said foamable composition (7) is applied with a degree of overpacking of less than 100%, the degree of overpacking being equal to: EPMATHMARKEREP wherein the moulded density of the further foam is equal to: EPMATHMARKEREP 
Postupak prema zahtjevu 1, naznačen time da pjenasti sastav (7) bude nanešen jednim stupnjem prekrivanja pri sprejanju manjem od 100%, pri čemu stupanj prekrivanja sprejanja odgovara: [image] pri čemu gustoća kalupljenja daljnje pjenaste tvari odgovara:
A process according to any one of the claims 1 to 3, characterised in that at least 80 vol. 
Postupak prema jednom od zahtjeva 1 do 3, naznačen time da je najmanje 80 vol.
A process according to any one of the claims 1 to 4. characterised in that said open-cell foam comprises a reticulated foam. 
Postupak prema jednom od zahtjeva 1 do 4, naznačen time da stanično otvorena pjenasta tvar obuhvaća jednu retikuliranu pjenastu tvar.
A process according to claim 6, characterised in that, in its uncompressed state, the open-cell foam in said core layer has an average thickness which is at least equal to said average cell size but smaller than twenty times said average cell size. 
Postupak prema zahtjevu 6, naznačen time da staničnootvorena pjenasta tvar u svom ne-stiješnjenom stanju u jezgrenom sloju pokazuje prosječnu debljinu, koja je najmanje istovjetna prosječnoj veličini stanica, ali je manja za 20-struko od prosječne veličine stanica.
A process according to any one of the claims 1 to 7, characterised in that the open-cell foam consists of a material which does not absorb the foamable composition. 
Postupak prema jednom od zahtjeva 1 do 7, naznačen time da se staničnootvorena pjenasta tvar sastoji od materijala, koji ne apsorbira pjenasti sastav.
A process according to any one of the claims 1 to 8, characterised in that said foamable composition (7) has a dynamic viscosity, measured at a shear rate of 1/s, of lower than 800 mPa.s when arriving onto the core layer (1). 
Postupak prema jednom od zahtjeva 1 do 8, naznačen time da pjenasti sastav (7), prema mjerenju, kod brzine smicanja od 1/s pokazuje dinamičku viskoznost od manje nego 800 mPa, ako dospije na jezgreni sloj (1).
A process according to any one of the claims 1 to 9, characterised in that at least 75 wt. % of said foamable composition (7) is applied by spraying it onto the core layer (1) while holding the core layer (1) in said lying position. 
Postupak prema jednom od zahtjeva 1 do 9, naznačen time da najmanje 75 tež.% pjenastog sastava (7) bude naneseno sprejanjem jezgrenog sloja (1), tijekom kojeg jezgreni sloj (1) bude držan u ležećem položaju.
A process according to any one of the claims 1 to 11, characterised in that the foamable composition (7) is sprayed on a first side of the core layer (1) and the core layer (1) has a second side, opposite the first side, which second side is covered with at least one second cover layer (2). 
Postupak prema jednom od zahtjeva 1 do 11, naznačen time da pjenasti sastav (7) bude sprejan na prvu stranu jezgrenog sloja (1), a jezgreni sloj (1) sadrži i drugu stranu, koja leži nasuprot prvoj strani, pri čemu je druga strana prekrivena s najmanje jednim drugim pokrovnim slojem (2).
A process according to any one of the claims 1 to 13, characterised in that said open-cell foam has a density of less than 60 kg/m3. 
Postupak prema jednom od zahtjeva 1 do 13, naznačen time da staničnootvorena pjenasta tvar pokazuje gustoću manju od 60 kg/m3.
A process according to any one of the claims 1 to 14, characterised in that said open-cell foam has an open-cell content of at least 95%. 
Postupak prema jednom od zahtjeva 1 do 14, naznačen time da staničnootvorena pjenasta tvar pokazuje sadržaj otvorenih stanica od najmanje 95%.